Effect of growth hormone-releasing peptide-2 (GHRP-2) and GH-releasing hormone (GHRH) on the the cAMP levels and GH release from cultured acromegalic tumours.

Chen C, Pullar M, Loneragan K, Zhang J, Clarke IJ

Journal of neuroendocrinology1 Jun 1998Cited by 8 (Europe PMC)

PMID9688350DOI10.1046/j.1365-2826.1998.00233.xPepBankPUB-09688350

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueActivity measurement
Application of GHRP‑2 for 30 min significantly increased GH secretion from cultured cells of all seven human acromegalic tumours.
In plain wordsIn cultured cells from seven human acromegalic tumours, GHRP‑2 raised growth hormone release in every tumour.
Peptide
GHRP-2
Outcome
IncreaseGH secretion from cultured tumours
Study
humann = 7
Primary cultures of human acromegalic tumour cells
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 30 minAs given in this study (human).
Source sentences
Summary
Application of GHRP-2 for 30 min induced a significant increase in GH secretion from the cultured cells from all seven tumours
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, cells were obtained from seven human acromegalic tumours and the effects of GHRP-2 were studied. Cells were dissociated and kept in primary culture for 1-3 weeks before experimentation.
Report a problemFND-0968835001
02LabEx vivo tissueActivity measurement
In cultured human acromegalic tumour cells, GHRP‑2 raised GH secretion in all seven tumours, while hGHRH 10 nM did so in only four of seven.
In plain wordsIn cultured cells from acromegalic tumours, GHRP‑2 raised growth hormone release in all seven tumours. GHRH did so in four of seven.
Peptide
GHRP-2
Outcome
IncreaseGH release with GHRP-2 versus GHRH
Study
humann = 7
Primary cultures of human acromegalic tumour cells
Comparator
hGHRH 10 nM
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Application of GHRP-2 for 30 min induced a significant increase in GH secretion from the cultured cells from all seven tumours whereas human GH-releasing hormone (hGHRH) at a dose of 10 nM induced a significant GH release in only four of seven tumours.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, cells were obtained from seven human acromegalic tumours and the effects of GHRP-2 were studied. Cells were dissociated and kept in primary culture for 1-3 weeks before experimentation.
Report a problemFND-0968835002
03LabEx vivo tissueMechanism
In cultured human acromegalic tumour cells, 10 nM GHRP‑2 significantly increased intracellular cAMP in all seven tumours, less than GHRH did.
In plain wordsIn cultured acromegalic tumour cells, GHRP‑2 raised the cell messenger cAMP in all seven tumours, but less than GHRH did.
Peptide
GHRP-2
Outcome
IncreaseIntracellular cAMP
Study
humann = 7
Primary cultures of human acromegalic tumour cells
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
10 nMAs given in this study (human).
Source sentences
Summary
The intracellular levels of cAMP in all seven tumours were significantly increased by both 10 nM GHRP-2 and GHRH, but the response to GHRH was significantly higher than the response to GHRP-2.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, cells were obtained from seven human acromegalic tumours and the effects of GHRP-2 were studied. Cells were dissociated and kept in primary culture for 1-3 weeks before experimentation.
Report a problemFND-0968835003
04LabEx vivo tissueMechanism
The adenylyl cyclase inhibitor MDL 12330A blocked the effect of GHRP‑2 on intracellular cAMP in cultured human acromegalic tumour cells.
In plain wordsIn cultured acromegalic tumour cells, a drug that blocks cAMP production stopped the cAMP rise caused by GHRP‑2.
Peptide
GHRP-2
Outcome
DecreasecAMP response to GHRP-2 with adenylyl cyclase inhibitor
Study
humann = 7
Primary cultures of human acromegalic tumour cells
Comparator
MDL 12330A
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
The adenylyl cyclase inhibitor, MDL 12330A, blocked the effect of GHRH and GHRP-2 on intracellular cAMP levels
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, cells were obtained from seven human acromegalic tumours and the effects of GHRP-2 were studied. Cells were dissociated and kept in primary culture for 1-3 weeks before experimentation.
Report a problemFND-0968835004
05LabEx vivo tissueMechanism
The Ca2+ channel blocker Co2+ did not attenuate the cAMP response in cultured human acromegalic tumour cells.
In plain wordsIn cultured acromegalic tumour cells, blocking calcium channels did not reduce the cAMP rise.
Peptide
GHRP-2
Outcome
No significant changecAMP response to GHRP-2 with Ca2+ channel blocker
Study
humann = 7
Primary cultures of human acromegalic tumour cells
Comparator
Co2+ 0.5 mM
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
the Ca2+ channel blocker Co2+ (0.5 mM) did not attenuate the cAMP response.
2 context sentences(design, population, supporting numbers)
Summary · context
The intracellular levels of cAMP in all seven tumours were significantly increased by both 10 nM GHRP-2 and GHRH, but the response to GHRH was significantly higher than the response to GHRP-2.
Summary · context
In the present study, cells were obtained from seven human acromegalic tumours and the effects of GHRP-2 were studied. Cells were dissociated and kept in primary culture for 1-3 weeks before experimentation.
Report a problemFND-0968835005
06LabEx vivo tissueMechanism
GHRP‑2 increased the intracellular Ca2+ concentration in a concentration-dependent manner in cultured human acromegalic tumour cells.
In plain wordsIn cultured acromegalic tumour cells, GHRP‑2 raised calcium inside the cells in a way that depended on the concentration.
Peptide
GHRP-2
Outcome
IncreaseIntracellular Ca2+ concentration
Study
humann = 7
Primary cultures of human acromegalic tumour cells
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Both GHRH and GHRP-2 increased the intracellular Ca2+ concentration in a concentration-dependent manner.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, cells were obtained from seven human acromegalic tumours and the effects of GHRP-2 were studied. Cells were dissociated and kept in primary culture for 1-3 weeks before experimentation.
Report a problemFND-0968835009
07LabEx vivo tissueMechanism
The cAMP antagonist Rp-cAMP did not block the GH response to GHRP‑2 in cultured human acromegalic tumour cells, but it blocked the response to GHRH.
In plain wordsIn cultured acromegalic tumour cells, a cAMP blocker did not stop the GHRP‑2 growth hormone response. It did stop the GHRH response.
Peptide
GHRP-2
Outcome
No significant changeGH response to GHRP-2 with cAMP antagonist
Study
humann: not reported in source
Primary cultures of human acromegalic tumour cells
Comparator
Rp-cAMP
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
For the tumours in which GH secretion was increased by GHRH and GHRP-2, the cAMP antagonist Rp-cAMP blocked the GH response to GHRH but not to GHRP-2.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, cells were obtained from seven human acromegalic tumours and the effects of GHRP-2 were studied. Cells were dissociated and kept in primary culture for 1-3 weeks before experimentation.
Report a problemFND-0968835006
08LabEx vivo tissueMechanism
The PKA inhibitor H89 did not alter the response to GHRP‑2 in cultured human acromegalic tumour cells.
In plain wordsIn cultured acromegalic tumour cells, a PKA blocker did not change the GHRP‑2 response.
Peptide
GHRP-2
Outcome
No significant changeGHRP-2 response with PKA inhibitor
Study
humann: not reported in source
Primary cultures of human acromegalic tumour cells
Comparator
H89
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
The response to GHRP-2 was not altered by H89.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, cells were obtained from seven human acromegalic tumours and the effects of GHRP-2 were studied. Cells were dissociated and kept in primary culture for 1-3 weeks before experimentation.
Report a problemFND-0968835007
09LabEx vivo tissueMechanism
The PKC inhibitor calphostin C reduced the effect of GHRP‑2 on GH secretion in cultured human acromegalic tumour cells.
In plain wordsIn cultured acromegalic tumour cells, a PKC blocker reduced the growth hormone release caused by GHRP‑2.
Peptide
GHRP-2
Outcome
DecreaseGH secretion response to GHRP-2 with PKC inhibitor
Study
humann: not reported in source
Primary cultures of human acromegalic tumour cells
Comparator
Calphostin C
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Calphostin C [a protein kinase C (PKC) inhibitor] reduced the effect of GHRP-2 on the secretion of GH
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, cells were obtained from seven human acromegalic tumours and the effects of GHRP-2 were studied. Cells were dissociated and kept in primary culture for 1-3 weeks before experimentation.
Report a problemFND-0968835008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.